

Metabolic Syndrome	3
Introduction to Metabolic Syndrome:	3
Describe what is meant by the term 'Metabolic Syndrome'	3
Explain the significance of the overall features of Metabolic Syndrome	3
Recognize the clinical criteria used to define Metabolic Syndrome and the factors that make this complicated	3
Describe the different roles of plasma lipoproteins in lipid transport. Rationalise the 'good' and 'bad' labels applied to cholesterol in terms of lipid transport pathways and the specific roles of lipoprotein complexes	3
Compare and contrast the roles of plasma lipoproteins in lipid transport, in the endogenous, exogenous and reverse cholesterol transport pathways	3
Integrate the process of the formation of atherosclerotic plaques with lipoprotein and lipid transport	4
Extra Information	4
Cholesterol Synthesis & Inhibition	4
Blood Pressure & Blood Glucose Measurement	5
Contributing Factors to MetS	5
Metabolic Syndrome as a Social and Political Sickness	5
Determine population health triggers for metabolic syndrome.	5
Describe obesity in developed countries as a function of inequality.	5
Discuss the contribution of epigenetics and changes in activity levels towards the obesity trend.	6
Explain how the metabolic syndrome epidemic arose from changes in food production, prices and profit.	6
Extra Information	6
Feeding and Weight Control	6
Describe how peripheral satiety and adiposity signals regulate body weight.	6
Explain how hypothalamic neuropeptides are involved in regulating body weight.	7
Describe the counterregulatory mechanisms that make it difficult to maintain weight loss.	7
Explain the hedonic (reward) signals involved in appetite regulation.	7
Extra information	8
The obesogenic environment includes several factors:	8
Cardiovascular Risk Factors	8
Detail the risk factors for cardiovascular disease	8
Elaborate on the CV risk in the medical model and public health context	8
Explain the rise and fall of the CV disease "epidemic"	8
Understand assessment of cardiovascular risk in metabolic syndrome patients	9
Explain why metabolic syndrome is a useful concept	9
Review some pharmacological options and lifestyle modifications	9
Obesity Resistance	9
Describe the significance of the Obesity problem worldwide and around Australia	9
Describe what the setpoint of body weight is and how body weight is regulated	9
Describe the causes and complications of Obesity	10
Explain how obesity resistance can inform us of what mechanisms are involved in obesity development through research led evidence: the gut as the second brain	10
Extra Information	10
Obesity Assessment Methods	10
Management Approaches	10
Pharmacotherapy	10
Type 2 Diabetes: Prevalence, Causes, and Treatment	11
Explain what Diabetes is and describe the significance of the problem worldwide and around Australia	11
Describe the pathways involved in maintaining glucose homeostasis	11
Describe the causes of Type 2 Diabetes	11
Describe what beta-cell dysfunction is and the underlying mechanisms causing this defect	12
Be led through a research paper and explain how basic research informs us of potential mechanisms and addressing gaps in knowledge	12
Describe what the current treatments are for Type 2 Diabetes	12
The Gut Microbiome and Metabolic Syndrome	13
Understand how changes in Western diet have impacted on the human gut microbiome	13
Understand how changes in the gut microbiota can contribute to diabetes and metabolic syndrome	13
Understand the role of short chain fatty acids in gut health and immunity	13
Be able to give examples of connections between diet, gut microbiota metabolism and generation of functionally important metabolites	14
Stem Cells and Tissue Engineering	14
Introduction to Stem Cells	14
Extra Information	14
Fertilization & Early Development	14
Assisted Reproduction (IVF)	14
Gastrulation (Day 15-16)	14
Organogenesis (First Trimester)	15
Cell Differentiation & Gene Regulation	15
Tissue Homeostasis	15
Articulate the definition of a stem cell and able to differentiate between totipotent, pluripotent and multipotent cells	15
Briefly discuss the role of adult tissue stem cells in tissue repair and homeostasis	16
Describe the distinct sources of pluripotent stem cells, how pluripotency can be demonstrated, and how these cells can be used	16
Outline how stem cells are likely to influence medicine.	17
Tissue Stem Cells	17
Describe tissue stem cells using examples including haematopoietic stem cells and mesenchymal stromal cells (and later, intestinal stem cells).	17
• Potential - what can they do?	17
Derivation – Sources of HSCs	17
Niche	18
Hierarchy	18
Potential	18
Derivation – Where can MSCs be isolated from?	19
Niche – Where do they reside?	19
Hierarchy – How are they organised?	19
Potential – What can they do?	19
Discuss the factors that have contributed to the 'MSC mess'.	19
Stem Cells as Cellular Therapy and for Endogenous Repair	20
Discuss the use of stem cells as cellular therapy broadly.	20
Provide a description of haematopoiesis and the role of Haematopoietic Stem Cells (HSCs).	20
Discuss bone marrow transplantation as a cellular therapy for blood disorders, including what cells and where from, complications of haematopoietic stem cell transplantation.	20
Outline the use of gene editing for correction of genetic diseases and for CAR immunotherapy	21
Cell and Gene Therapies - Current	22
Create awareness of the Australian regulations for advanced therapies.	22
Understand basic principles of gene therapy.	22
Be familiar with the scientific rationale of current cell and gene therapies.	23
Cell and Gene Therapies - Future	23
Be familiar with the scientific rationale of future cell and gene therapies and Be introduced to pioneering patients who first received these therapies.	23
Future-facing therapies including iPSC-derived tissues.	24
Considerations of the clinical trial pipeline	25
Risks and strategies to manage risks of Cell and Gene Therapy (CAGT)	25
Stem Cell Technologies - Gastrointestinal Stem Cells, Organoids, and Introduction to Tissue Engineering	26
Describe tissue stem cells using the example of gastrointestinal stem cells. Considerations should include:	26
o Derivation - where do they come from?	26
o Niche - where do they reside?	26
o Hierarchy - how are they organised?	26
o Potential - what can they do?	26
1. Derivation – Where do they come from?	26
2. Niche – Where do they reside?	26
3. Hierarchy – How are they organised?	26
4. Potential – What can they do?	27
5. Experimental Evidence	27
Be able to describe organoids – source, process of formation, and description.	27
Be able to discuss the utility of organoids in disease modelling. Be able to discuss the utility of organoids in drug discovery.	27
Describe basic tissue engineering principles including:	28
• Potential application	28
• Design considerations: cells, scaffold, signalling molecules, vasculature	28
• Limitations	28
Potential Applications	28
Design Considerations	28
Limitations / Challenges	28
Tissue Engineering - In Vitro Meat	29
Biomaterials and Biofabrication for Tissue Engineering	29

Describe the roles and significance of biomaterials in tissue engineering	29
Appreciate the design criteria and some of the processes used to select, fabricate and tailor biomaterials for tissue engineering	30
Understand the key limitations and challenges of using biomaterials in tissue engineering	30
Respiratory Diseases	31
Asthma (Obstructive)	31
COPD (Chronic Obstructive Pulmonary Disease)	31
Interstitial Lung Disease (Restrictive)	31
Have an appreciation for the development of the respiratory system	32
Describe the current understanding of the organisation of respiratory stem cells in the adult lung	32
Recognise the importance of epithelial—mesenchymal interactions in the lung (and other tissues)	32
Be able to consider the challenges in using stem cells for therapeutic application in lung diseases.	33
Healthy Lungs for Life	33
The two commonly used lung function measures (i.e. FEV1 and FVC) and how they can be used to identify the types of lung function impairments	33
Age related variation in lung function	33
Lifetime lung function trajectory can vary across individuals	34
Different lung function trajectories have different consequences	34
There are multiple risk factors that influence lung function trajectories and thereby lung function impairment throughout life	34
Implications on clinical and public health practice, and future research.	34
Big Tobacco and the Global Burden of Disease	34
Describe the benefit of population health approaches versus individual approaches	35
Discuss what works in tobacco control to decrease tobacco related harm	35
Be critical of industry involvement in public health	35
Explain what is the tobacco endgame	36
Discuss some of the approaches proposed to push towards the endgame for tobacco use in Australia.	36
Chronic Obstructive Pulmonary Disease (COPD) and Pre COPD	36
The concept of whole-of-life disease trajectories	36
COPD as a systemic disease with multiple comorbidities	36
The important role of infection and recurrent exacerbations and effects of treatments	38
The basis for bronchodilator therapy and be able to explain how irreversible changes in Lung structure cause airflow limitation and how this is worsened by inflammation	38
The current controversy on the role of inhaled steroids and anti-eosinophil therapy	39
How Can We Cure Asthma?	40
Describe the clinical and pathophysiological characteristics of asthma	40
Understand recent advances in non-invasive and minimally invasive clinical methods for diagnosis and research	40
Describe the rationale and mechanism of action of current asthma pharmacotherapies, including inhaled therapies and biologics	41
Debate why SABAs remain the most-common therapy despite changes in clinical guidelines >5 years ago	42
Evaluate emerging concepts such as treatment-induced asthma remission	42
Describe what a curative therapy might look like and the knowledge gaps that must be filled to achieve this	42
Articulate the challenges of redefining asthma from a “manageable” condition to a curable one	42
Lung Cancer: Epidemiology, Biology, and Treatment	43
List the diverse types of lung cancer	43
Epidemiology	43
Understand oncogenic drivers in lung cancer	43
Explain the rationale for different therapeutic approaches	43
Understand how tumour cells respond to their interaction with the immune system: immune evasion mechanisms.	44
Advanced Modalities , T2 Infection, Mucus, and Viruses	44
Why do we need “advanced modalities”? As an example, what can an inhaled anticalin based medicine do that do that, monoclonal antibody can't do....and what are intrinsic limitations of monoclonal antibodies that limit their utility in lung disease (e.g large size and fragile structure make aerosols tricky whereas inject monoclonals have poor bioavailability to the epithelium).....what other factors are important here??	44
Be able to use case studies to understand general principals: Case study PRS-060 (elarekibep) vs duplumab.	45
Why is mucus such an issue in lung medicine? How can we use the biology of JAG-1 to target mucus overproduction and clearance....(think about the balance between mucus forming goblet cells and ciliated cells....who does this biology mesh with our framework understanding of lung development and cell lineage differentiation? How does this biology relate to choice of drug technology): Case study PRS-400	45
Why are viral infections so important in respiratory medicine: exacerbations, facilitating bacterial outgrowth, driving progression ... What other factors are important, If viral lung disease is so important, why was the nose emphasized in the lecture?	46
How do we exploit the nasal biology of viral infections to create new treatment strategies? Can you exemplify your understanding of this with the Case studies; heparin and INNA-051?	46
Breakthrough in Respiratory Health - International Update	47
Know the mode of action of Ensifentrine for COPD and Bresocaticb for bronchiectasis.	47
Why is the endotype concept useful and what are examples of endotype targeted therapy	48
Articulate how research into Cystic fibrosis has led to progressive improvements. Be able to explain why triple “kafor” therapy is transformative	48
Consider lung development biology, trajectory analysis and epidemiology- Policy and public health interventions to (i) improve air quality (ii) lessen social disadvantage	48
Be able to discuss advances in lung cancer exemplified by targeted therapies	49
What are the limits of our current approaches	49
Understand how fundamental research can lead to actionable knowledge and consider how that knowledge could be used	50
Mental Health	51
Introduction to Mental Health	51
Define mental health and social determinants of mental health.	51
List the main mental disorders.	51
Explain the impact of being diagnosed with a mental disorder.	51
Explain the importance of culture and environment in relation to the diagnosis and the presence of mental disorders.	52
Explain the importance of addressing the life course social determinants of mental health.	52
Future Directions and Societal Strategies	52
Population Mental Health - Challenges and Opportunities	53
List the main types of mental disorders and their prevalence rates in Australia.	53
Explain the impact of having a mental disorder on the lives of people affected.	53
List the main priority areas of Australia's policy response to mental disorders.	53
Explain the spectrum of mental health interventions.	54
Define mental health literacy and the impact of research on mental health promotion in Australia.	54
Explain Australia's key primary mental healthcare reforms and their impacts.	54
Mental Health and Climate Change	55
Appreciate the key drivers, impacts and trends in climate change	55
Understand the direct and indirect pathways impacting mental health	55
Appreciate the impact of climate change on mental health services	56
Appreciate how researchers, communities & citizens can help mitigate the impact of climate change	56
Understand the benefits of climate action	56
All in Our Heads: The Neurobiology of Mental Illness	56
Be able to identify the key neuropathology associated with schizophrenia	57
Describe the dopamine systems involved in schizophrenia	57
Discuss medication used to treat schizophrenia and their effects (and side effects)	57
Major Depressive Disorder (MDD)	58
Describe the monoamine hypothesis and its relationship to depression	58
Discuss the inflammatory hypothesis and its relationship with depression	58
Articulate the rationale, effectiveness and use of antidepressant drugs (effects and side effects).	58
Non-Pharmacological & Environmental Approaches	59
Pots, Pills, and Psychedelics: Drugs in Mental Health	59
MDMA: Key mechanism of action and efficacy in PTSD	59
Palocycin: Key mechanism of action and efficacy in Depression	59
Cannabis: Key mechanism of action and efficacy as a treatment in Mental Health	60
Socioeconomic and Sociocultural Influences on Mental Health and Illness	61
Describe how rates of mental health problems in Australia vary with socioeconomic disadvantage of area.	61
Explain the Concentration index as a measure of inequity.	61
Differentiate clinical from personal recovery in mental health care.	61
Distinguish multiple usages of the term iatrogenesis.	61
Identify the influence of the term 'civil conscription' as used in the Australian constitution as an influence on healthcare policy.	62
Suicide Prevention - Population Based interventions	62
Describe the basic epidemiology of suicide in Australia;	62
List the broad categories of risk factors that contribute to suicide;	62
Explain the spectrum of suicide prevention interventions, and differentiate between universal, selective and indicated interventions;	63
Provide examples of specific interventions (that can be delivered at each of these levels, including some that might be helpful for mitigating risks of suicide associated with COVID-19;	64
Discuss potential reasons for why males have higher suicide rates than females, and describe some specific interventions that have been designed to prevent suicide in boys and men;	64
Articulate why strong evaluation is particularly important in this area.	64
Alcohol and Other Drugs in Mental Health	64
Developmental Pathway of Youth Substance Use	64
Explain how alcohol and drug use disorders are classified in relation to mental health disorders.	65
Summarise the epidemiology, distribution, and determinants of alcohol consumption, smoking and drug use in Australia.	65
Describe the genetic and biophysiological theories that explain how alcohol and drug use can lead to abuse and the long-term implications of their use.	65
Drug Wheel — Effects on the CNS	66
Understand the links between drug addiction and various types of mental health disorders and how substance misuse can influence the aetiology of neurological conditions. What is dual diagnosis?	66
Identify some of the more common treatment options available for substance abuse disorders and how these may differ in the presence of coexisting mental health disorders.	66
Identify strategies to minimise the risk of substance use having a long-term impact on mental and physical wellbeing.	67
Stigma reduction is arguably the most important intervention for AOD	67

Introduction to Metabolic Syndrome:

Describe what is meant by the term 'Metabolic Syndrome'

- Metabolic syndrome is best defined as a cluster of risk factors that predispose individuals to type 2 diabetes and cardiovascular disease.
- With an annual incidence of MetSy thought to be 3% and more than 35% of Australian adults have metabolic syndrome (BHC).
- Studies show that more women than men in the same age groups tend to meet the criteria for metabolic syndrome, with prevalence increasing with age. Women aged 60-78 have a particularly high prevalence, with over a third affected. The risk increases as individuals grow older, especially among females.

Explain the significance of the overall features of Metabolic Syndrome

- Hypertension: arises from insulin resistance, endothelial dysfunction, and increased sympathetic nervous system activity = CV risk
- High triglycerides, low HDL cholesterol, small dense LDL particles: accelerates plaque formation = CV risk
 - Excess triglycerides can also accumulate in the pancreas, leading to pancreatitis
 - **Small, dense LDL** (often with high triglycerides) penetrate vessel walls more easily → ↑ atherosclerosis risk = **Apolipoprotein particle count** gives a better risk assessment than LDL concentration
- Insulin resistance/Raised fasting blood glucose levels: hyperinsulinemia (pancreas compensate) = β-cell exhaustion + insulin resistance, predisposing to T2DM.
 - Damages micro/macrovaskulature → ↑ inflammation & oxidative stress
 - Complications: neuropathy, nephropathy, retinopathy, erectile dysfunction, poor wound healing, cognitive decline
 - Although 25% of insulin resistant patients have normal glucose tolerance
 - **High HbA1c** → poor glucose regulation → ↑ risk of stroke and myocardial infarction. Cardiovascular risk rises with hyperglycemia **even before diabetes develops**.
- Central obesity (excess fat around the abdomen): metabolically active, releasing free fatty acids, pro-inflammatory cytokines, and adipokines that promote insulin resistance = CV risk and T2D
 - Waist circumference increasingly preferred over BMI (e.g. Norway)
 - Highlights **visceral fat** as stronger risk factor than general obesity

Recognize the clinical criteria used to define Metabolic Syndrome and the factors that make this complicated

- Diagnosis requires meeting at least three out of these five criteria.
- Complicating factors:
 - **Different organisation** criterias: Mayo Clinic, American Heart Association, RACGP (Australian), and IDF
 - **Ethnic** differences: South Asians and Southeast Asians tend to have higher visceral fat at lower waist measurements
 - Overlap with related conditions: T2D, obesity, hypertension
 - Dynamic nature of risk: change numbers easily
 - **Fat distributions** (external SC vs internal visceral): visceral fat, also called hidden fat, surrounds internal organs and is linked to metabolic issues. It secretes less hormones like leptin, which helps regulate appetite. Visceral fat is associated with higher cortisol levels, which can influence stress and metabolic health. Individuals can be fat and fit or metabolically obese and thin outside, fat inside (TOFI). Visceral fat is associated with metabolic derangements – insulin resistance, high triglycerides, inflammation, altered cytokine levels.

Describe the different roles of plasma lipoproteins in lipid transport. Rationalise the 'good' and 'bad' labels applied to cholesterol in terms of lipid transport pathways and the specific roles of lipoprotein complexes

- Carry triglycerides (high energy), cholesterol, phospholipids in blood
- When food is ingested, dietary fats are emulsified by bile salts in the intestine, breaking them into smaller droplets. Lipases then digest triglycerides into their component parts. These are reassembled into triglycerides within intestinal mucosa and packaged into chylomicrons for transport.
- **Chylomicrons (dietary/exogenous pathway)**
 - Origin: intestine (after meals)
 - Cargo: dietary TG + cholesterol
 - Function: deliver TG → adipose (storage), muscle (energy)
- **VLDL (endogenous pathway)**
 - Origin: liver
 - Cargo: endogenous TG (made in liver)
 - Function: deliver TG → tissues; become IDL → LDL
- **LDL ("bad cholesterol")**
 - Origin: from IDL after TG removal
 - Cargo: cholesterol (esp. esters)
 - Function: deliver cholesterol → tissues (membranes, steroid hormones)
 - Clinical: excess LDL → arterial wall deposition → atherosclerosis
- **HDL ("good cholesterol")**
 - Origin: liver and intestine (nascent HDL)
 - Cargo: cholesterol collected from tissues
 - Function: reverse cholesterol transport → liver (excretion or transfer to LDL/VLDL via CETP)
 - Also donates ApoC-II & ApoE to other lipoproteins
 - Protective against CVD

	Mayo clinic	American Heart Association & NHLBI	RACGP	New IDF definition
Large waist	> 102cm in men > 89cm in women	> 102cm in men > 89cm in women	> 90-102cm in men > 80cm in women	Ethnic specific values
High triglyceride levels (or drug treatment)	> 1.7 mmol/L	> 1.7 mmol/L	> 1.7 mmol/L	> 1.7 mmol/L
Reduced HDL (or drug treatment)	< 1.04 mmol/L in men < 1.3 mmol/L in women	< 1.05 mmol/L in men < 1.3 mmol/L in women	< 1.0 mmol/L in men < 1.3 mmol/L in women	< 1.03 mmol/L in men < 1.29 mmol/L in women
Elevated blood pressure (or drug treatment)	> 130 systolic > 85 diastolic	> 130 systolic > 85 diastolic	> 130 systolic > 85 diastolic	> 130 systolic > 85 diastolic
Elevated fasting glucose (or drug treatment)	> 5.6 mmol/L	> 5.6 mmol/L	> 5.6 mmol/L	> 5.6 mmol/L

Compare and contrast the roles of plasma lipoproteins in lipid transport, in the endogenous, exogenous and reverse cholesterol transport pathways

Exogenous Pathway (Dietary Lipids)

- **Lipoprotein:** Chylomicrone
- **Source:** Intestine (enterocytes, after meals)
- **Cargo:** Dietary TAGs, cholesterol, cholesterol esters
- **Role:**
 - Deliver TAGs → adipose (storage), muscle (energy), mammary gland (lactation)
 - After lipid delivery → chylomicron remnants → liver → degraded in lysosomes
- **Key point:** Handles exogenous (dietary) fat transport

Endogenous Pathway (Liver-Derived Lipids)

- Triggered when dietary intake of fatty acids, cholesterol, and carbohydrates (which can be converted to TAGs) is high.
- **Lipoprotein:** VLDL → IDL → LDL
- **Source:** Liver (esp. when intake of fatty acids, cholesterol, carbs is high)
- **Process:**
 - FFAs → TAGs; cholesterol → cholesterol esters → packaged into VLDL
 - **VLDL roles:**
 - High insulin → TAGs → adipose (storage)
 - Low insulin → TAGs mobilized → muscle (oxidation/energy)
 - TAG removal from VLDL → VLDL → IDL → LDL (cholesterol-rich)
- **LDL roles:**
 - Delivers cholesterol → tissues (muscle, adrenal, adipose)
 - Also to macrophages → foam cell formation → atherosclerosis risk
 - Excess LDL → liver (membrane synthesis, bile acids, cholesterol ester storage)
- **Clinical:** LDL = "bad cholesterol"

Reverse Cholesterol Transport (Protective Pathway)

- **Lipoprotein:** HDL
- **Source:** Liver & small intestine (nascent HDL)
- **Role:**
 - HDL acts as cholesterol scavenger → collects cholesterol from tissues, macrophages, foam cells
 - Returns cholesterol → liver (direct uptake or transfer to LDL/VLDL via CETP)
- **Clinical:** Protects against atherosclerosis → HDL = "good cholesterol"

Enterohepatic Pathway (Cholesterol Recycling)

- **Role of Liver:** Uses cholesterol to synthesize bile salts
- **Role in Transport:** Bile salts secreted into intestine → majority reabsorbed → returned to liver/gallbladder for reuse
- **Link:** Connects cholesterol metabolism with lipid digestion/absorption

Integrate the process of the **formation of atherosclerotic plaques** with lipoprotein and lipid transport

Cholesterol Background

- ~35 g cholesterol in 75 kg man (membranes, hormones, bile salts, vitamin D)
- Synthesized mainly by liver (~1 g/day, ~80% of body needs)
- Not present in plants → diet not essential for supply

Role of Lipoproteins in Atherosclerosis

- **LDL** (cholesterol-rich, from endogenous pathway) = main driver of atherogenesis
- High circulating LDL → cholesterol deposition in vessel wall
- **HDL** (reverse transport) → protective, removes cholesterol from tissues/plaques
- Dyslipidemia (↑LDL, ↓HDL) = major risk factor

Pathogenesis of Atherosclerosis

1. **Endothelial Injury/Dysfunction**
 - Causes: hypertension, smoking, diabetes, hyperlipidemia
 - Damaged endothelium → ↑permeability to LDL, expression of adhesion molecules
2. **LDL Entry & Modification**
 - LDL enters intima → becomes **oxidized/modified LDL**
 - Modified LDL is highly atherogenic
3. **Inflammatory Response**
 - Endothelial activation → attracts **monocytes & T-cells**
 - Monocytes migrate → intima → differentiate into macrophages
4. **Foam Cell Formation**
 - Macrophages engulf oxidized LDL via scavenger receptors
 - Cholesterol-laden macrophages = **foam cells**
 - Accumulation of foam cells → **fatty streaks** (earliest lesion)
5. **Plaque (Atheroma) Development**
 - Smooth muscle cells migrate into intima → secrete extracellular matrix → **fibrous cap** forms
 - Core of plaque = cholesterol + foam cells + necrotic debris
 - Results in arterial **narrowing & stiffening** → ↓blood flow
6. **Plaque Rupture & Thrombosis**
 - Thin/unstable fibrous cap may rupture
 - Foam cells release **tissue factor** → activates clotting cascade
 - Platelet aggregation + thrombus formation → possible **arterial occlusion**
 - Outcomes:
 - Coronary arteries → **myocardial infarction**
 - Cerebral arteries → **stroke**
 - Peripheral arteries → **peripheral arterial disease**

Extra Information

Cholesterol Synthesis & Inhibition

- Cholesterol mainly synthesized in body (~80%) from **acetyl-CoA**
- Rate-limiting enzyme: **HMG-CoA reductase**
- **Statins** = competitive inhibitors → ↓ cholesterol synthesis
- Normally feedback-regulated, but statins provide effective pharmacological control